Luxendo, a microscope manufacturer spun out of the European Molecular Biology Laboratory (EMBL), has extended its series A round to €8m ($8.4m) today.
EMBL Ventures and EMBL Enterprise Management Technology Transfer (Emblem), the institute’s investment arm and commercialisation office, respectively, supported the €2m extension, as did Life Science Partners.
EMBL Ventures and Life Science Partners had provided an initial €6m series A tranche in 2015.
Luxendo is developing microscopes based on its single plane illumination technology (Spim), which enable researchers to observe organisms for prolonged period by sequentially illuminating a stack of slices (of up to a few micrometres in size) of the organism to avoid photo-toxicity.
The additional cash will drive recruitment of Luxendo’s international sales and marketing teams. The company will also invest in its production capacity.
Jürgen Bauer, deputy managing director of Emblem, said: “We are pleased that with Luxendo, the most recent Spim technologies company to come out of EMBL is focused on making its products available to the wider scientific community as rapidly as possible. This increased series A financing will help it speed up this process.”
